Advertisement

Progestins and breast cancer

      Abstract

      The relationship between the use of menopausal hormone therapy (ERT, unopposed estrogen therapy; HRT, combined estrogen and progestin therapy) and the development of breast cancer remains controversial. Mechanistic studies examining progestins in human breast cancer cell lines have demonstrated a biphasic cellular response to progesterone; initial exposure to hormone results in a proliferative burst with sustained exposure resulting in growth inhibition. To date, there is no definitive evidence that progestins act in the pathogenesis of breast cancer. Epidemiologic studies have produced inconsistent results, and data from randomized, placebo-controlled trials are limited. Although recent results from the continuous combined therapy arm of the Women's Health Initiative trial showed a small increase in the risk of invasive breast cancer in women on therapy for 5 years or more, a clear consensus regarding the relationship between HRT and breast cancer risk cannot yet be drawn from existing data. Studies have consistently documented that HRT use is associated with improved mortality and survival rates for women with breast cancer. Large-scale, randomized studies on different progestin regimens are needed to critically assess the effect of progestin on breast cancer. (Am J Obstet Gynecol 2003;188:1123-31.)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • American Cancer Society
        Cancer facts and figures—1998.
        American Cancer Society, Atlanta (GA)1998
        • Schneider HP.
        HRT and cancer risk: separating fact from fiction.
        Maturitas. 1999; 33: S65-S72
        • Miki Y
        • Swensen J
        • Shattuck-Eidens D
        • Futreal PA
        • Harshman K
        • Tavtigian S
        • et al.
        A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
        Science. 1994; 266: 66-71
        • Wooster R
        • Neuhausen SL
        • Mangion J
        • Quirk Y
        • Ford D
        • Collins N
        • et al.
        Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.
        Science. 1994; 265: 2088-2090
        • Johnson SR.
        Menopause and hormone replacement therapy.
        Med Clin North Am. 1998; 82: 297-320
        • Cauley JA
        • Seeley DG
        • Ensrud K
        • Ettinger B
        • Black D
        • Cummings SR
        • et al.
        Estrogen replacement therapy and fractures in older women.
        Ann Intern Med. 1995; 122: 9-16
        • Notelovitz M.
        Estrogen therapy and osteoporosis: principles and practice.
        Am J Med Sci. 1997; 313: 2-12
        • Brunelli MP
        • Einhorn TA.
        Medical management of osteoporosis: fracture prevention.
        Clin Orthop. 1998; 348: 15-21
        • Eastell R.
        Treatment of postmenopausal osteoporosis.
        N Engl J Med. 1998; 338: 736-746
        • Mosca L.
        The role of hormone replacement therapy in the prevention of postmenopausal heart disease.
        Arch Intern Med. 2000; 160: 2263-2272
        • Paganini-Hill A
        • Henderson VW.
        Estrogen replacement therapy and risk of Alzheimer disease.
        Arch Intern Med. 1996; 156: 2213-2217
        • Kawas C
        • Resnick S
        • Morrison A
        • Brookmeyer R
        • Corrada M
        • Zonderman A
        • et al.
        A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging.
        Neurology. 1997; 48: 1517-1521
        • Colditz GA
        • Hankinson SE
        • Hunter DJ
        • Willett WC
        • Manson JE
        • Stampfer MJ
        • et al.
        The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
        N Engl J Med. 1995; 332: 1589-1593
        • Schairer C
        • Lubin J
        • Triosi R
        • Sturgeon S
        • Brinton L
        • Hoover R.
        Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
        JAMA. 2000; 283: 485-491
        • Ross RK
        • Paganini-Hill A
        • Wan PC
        • Pike MC.
        Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
        J Natl Cancer Inst. 2000; 92: 328-332
        • Graham JD
        • Clarke CL.
        Physiological action of progesterone in target tissues.
        Endocr Rev. 1997; 18: 502-519
        • Clarke CL
        • Sutherland RL.
        Progestin regulation of cellular proliferation.
        Endocr Rev. 1990; 11: 266-301
        • Lydon JP
        • DeMayo FJ
        • Funk CR
        • Mani SK
        • Hughes AR
        • Montgomery Jr, CA
        • et al.
        Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities.
        Genes Dev. 1995; 9: 2266-2278
        • Humphreys RC
        • Lydon JP
        • O'Malley BW
        • Rosen JM.
        Use of PRKO mice to study the role of progesterone in mammary gland development.
        J Mammary Gland Biol Neoplasia. 1997; 2: 343-354
        • Sicinski P
        • Donaher JL
        • Parker SB
        • Li T
        • Fazeli A
        • Gardner H
        • et al.
        Cyclin D1 provides a link between development and oncogenesis in the retina and breast.
        Cell. 1995; 82: 621-630
        • Liu X
        • Robinson GW
        • Wagner KU
        • Garrett L
        • Wynshaw-Boris A
        • Hennighausen L.
        Stat5a is mandatory for adult mammary gland development and lactogenesis.
        Genes Dev. 1997; 11: 179-186
        • Udy GB
        • Towers RP
        • Snell RG
        • Wilkins RJ
        • Park SH
        • Ram PA
        • et al.
        Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression.
        Proc Natl Acad Sci U S A. 1997; 94: 7239-7244
        • Lange CA
        • Richer JK
        • Horwitz KB.
        Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals.
        Mol Endocrinol. 1999; 13: 829-836
        • Chang K-J
        • Lee TTY
        • Linares-Cruz G
        • Fournier S
        • De Lignieres B.
        Influences of percutaneous administration of estradiol and progesterone of human breast epithelial cell cycle in vivo.
        Fertil Steril. 1995; 63: 785-791
        • Foidart J-M
        • Colin C
        • Denoo X
        • Desreux J
        • Béliard A
        • Fournier S
        • et al.
        Estradiol and progesterone regulate the proliferation of human breast endothelial cells.
        Fertil Steril. 1998; 69: 963-969
        • Edery M
        • McGrath M
        • Larson L
        • Nandi S.
        Correlation between in vitro growth and regulation of estrogen and progesterone receptors in rat mammary epithelia cells.
        Endocrinology. 1984; 115: 1691-1697
        • McGrath M
        • Palmer S
        • Nandi S.
        Differential response of normal rat mammary epithelial cells to mammogenic hormones and EGF.
        J Cell Physiol. 1985; 125: 182-191
        • Malet C
        • Spritzer P
        • Guillaumin D
        • Kuttenn F.
        Progesterone effect on cell growth, ultrastructural aspect and estradiol receptors of normal human breast epithelial (HBE) cells in culture.
        J Steroid Biochem Mol Biol. 2000; 73: 171-181
        • Clark JH
        • Peck Jr., EJ
        Female sex steroids: receptors and function.
        Springer-Verlag, New York1979
        • McManus MJ
        • Welsch CW.
        The effect of estrogen, progesterone, thyroxine, and human placental lactogen on DNA synthesis of human breast ductal epithelium maintained in athymic nude mice.
        Cancer. 1984; 54: 1920-1927
        • Sutherland RL
        • Prall OW
        • Watts CK
        • Musgrove EA.
        Estrogen and progestin regulation of cell cycle progression.
        J Mammary Gland Biol Neoplasia. 1998; 3: 63-72
        • Groshong SD
        • Owen GI
        • Grimison B
        • Schauer IE
        • Todd MC
        • Langan TA
        • et al.
        Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27Kip1.
        Mol Endocrinol. 1997; 11: 1593-1607
        • Musgrove EA
        • Lee CS
        • Cornish AL
        • Swarbrick A
        • Sutherland RL.
        Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21.
        Mol Endocrinol. 1997; 11: 54-66
        • Hissom JR
        • Moore MR.
        Progestin effects on growth in the human breast cancer cell line T-47D—possible therapeutic implications.
        Biochem Biophys Res Commun. 1987; 145: 706-711
        • Musgrove EA
        • Lee CSL
        • Sutherland RL.
        Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor , epidermal growth factor receptor, c-fos , and c-myc genes.
        Mol Cell Biol. 1991; 11: 5032-5043
        • James VHT
        • McNeill JM
        • Lai LC
        • Newton CJ
        • Ghilchik MW
        • Reed MJ.
        Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies.
        Steroids. 1987; 50: 269-279
        • Blankenstein MA
        • Van DV
        • Maitimu-Smeele I
        • Donker GH
        • de Jong PC
        • Daroszewski J
        • et al.
        Intratumoral levels of estrogens in breast cancer.
        J Steroid Biochem Mol Biol. 1999; 69: 293-297
        • Bulun SE
        • Price TM
        • Aitken J
        • Mahendroo MS
        • Simpson ER.
        A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription.
        J Clin Endocrinol Metab. 1993; 77: 1622-1628
        • Miller WR.
        Aromatase activity in breast tissue.
        J Steroid Biochem Mol Biol. 1991; 39: 783-790
        • Murray R.
        Role of anti-aromatase agents in postmenopausal advanced breast cancer.
        Cancer Chemother Pharmacol. 2001; 48: 259-265
        • Iqbal S
        • Miller WR.
        New drugs in breast cancer.
        Exp Opin Pharmacother. 2001; 2: 975-985
        • Chetrite GS
        • Pasqualini JR.
        The selective estrogen enzyme modulator (SEEM) in breast cancer.
        J Steroid Biochem Mol Biol. 2001; 76: 95-104
        • Andersson S
        • Moghrabi N.
        Physiology and molecular genetics of 17-hydroxysteroid dehydrogenases.
        Steroids. 1997; 62: 143-147
        • Pollow K
        • Boquoi E
        • Baumann J
        • Schmidt-Gollwitzer M
        • Pollow B.
        Comparison of the in vitro conversion of estradiol-17 beta to estrone of normal and neoplastic human breast tissue.
        Mol Cell Endocrinol. 1977; 6: 333-348
        • Nguyen B-L
        • Chetrite G
        • Pasqualini JR.
        Transformation of estrone and estradiol in hormone-dependent and hormone-independent human breast cancer cells: effects of the antiestrogen ICI 164,384, danazol, and promegestone (R-5020).
        Breast Cancer Res Treat. 1995; 34: 139-146
        • Malet C
        • Vacca A
        • Kuttenn F
        • Mauvais-Jarvis P.
        17-Estradiol dehydrogenase (E2DH) activity in T47D cells.
        J Steroid Biochem Mol Biol. 1991; 39: 769-775
        • Fournier S
        • Brihmat F
        • Durand JC
        • Sterkers N
        • Martin PM
        • Kuttenn F
        • et al.
        Estradiol 17-hydroxysteroid dehydrogenase, a marker of breast cancer hormone dependency.
        Cancer Res. 1985; 45: 2895-2899
        • Pasqualini JR
        • Chetrite G
        • Nguyen B-L
        • Maloche C
        • Delalonde L
        • Talbi M
        • et al.
        Estrone sulfate-sulfatase and 17-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence.
        J Steroid Biochem Mol Biol. 1995; 53: 407-412
        • Chetrite G
        • Paris J
        • Botella J
        • Pasqualini JR.
        Effect of nomegestrol acetate on estrone-sulfatase and 17-hydroxysteroid dehydrogenase activities in human breast cancer cells.
        J Steroid Biochem Mol Biol. 1996; 58: 525-531
        • Chetrite GS
        • Ebert C
        • Wright F
        • Philippe J-C
        • Pasqualini JR.
        Effect of Medrogestone on 17-hydroxysteroid dehydrogenase activity in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines.
        J Steroid Biochem Mol Biol. 1999; 68: 51-56
        • Adams EF
        • Coldham NG
        • James VHT.
        Steroidal regulation of oestradiol-17 dehydrogenase activity of the human breast cancer cell line MCF-7.
        J Endocrinol. 1988; 118: 149-154
        • Coldham NG
        • James VHT.
        A possible mechanism for increased breast cell proliferation by progestins through increased reductive 17 beta-hydroxysteroid dehydrogenase activity.
        Int J Cancer. 1990; 45: 174-178
        • Miller WR
        • Mullen P.
        Factors influencing aromatase activity in the breast.
        J Steroid Biochem Mol Biol. 1993; 44: 597-604
        • Perel E
        • Daniilescu D
        • Kharlip L
        • Blackstein M
        • Killinger DW.
        Steroid modulation of aromatase activity in human cultured breast carcinoma cells.
        J Steroid Biochem. 1988; 29: 393-399
        • Chetrite GS
        • Ebert C
        • Wright F
        • Philippe A-C
        • Pasqualini JR.
        Control of sulfatase and sulfotransferase activities by medrogestone in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines.
        J Steroid Biochem Mol Biol. 1999; 70: 39-45
        • Chetrite G
        • Le Nestour E
        • Pasqualini JR.
        Human estrogen sulfotransferase (hEST1) activities and its mRNA in various breast cancer cell lines: effect of the progestin, promegestone (R-5020).
        J Steroid Biochem Mol Biol. 1998; 66: 295-302
        • Bush TL
        • Whiteman M
        • Flaws J.
        Hormone replacement therapy and breast cancer: a qualitative review.
        Obstet Gynecol. 2001; 98: 498-508
        • Campagnoli C
        • Biglia N
        • Cantamessa C
        • Lesca L
        • Sismondi P.
        HRT and breast cancer risk: a clue for interpreting the available data.
        Maturitas. 1999; 33: 185-190
        • Santen RJ
        • Pinkerton J
        • McCartney C
        • Petroni GR.
        Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy.
        J Clin Endocrinol Metab. 2001; 86: 16-23
        • Beral V
        • Banks E
        • Reeves G
        • Appleby P.
        Use of HRT and the subsequent risk of cancer.
        J Epidemiol Biostat. 1999; 4: 191-210
        • Collaborative Group on Hormonal Factors in Breast Cancer
        Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer.
        Lancet. 1997; 350: 1047-1059
        • Gambrell Jr, RD
        • Maier RC
        • Sanders BI.
        Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users.
        Obstet Gynecol. 1983; 62: 435-443
        • Ng E-H
        • Gao F
        • Ji C-Y
        • Ho G-H
        • Soo K-C.
        Risk factors for breast carcinoma in Singaporean Chinese women: the role of central obesity.
        Cancer. 1997; 80: 725-731
        • Magnusson C
        • Baron JA
        • Correia N
        • Bergström R
        • Adami H-O
        • Persson I.
        Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy.
        Int J Cancer. 1999; 81: 339-344
        • Colditz GA
        • Rosner B.
        Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study.
        Am J Epidemiol. 2000; 152: 950-964
        • Ewertz M.
        Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark.
        Int J Cancer. 1988; 42: 832-838
        • Kaufman DW
        • Palmer JR
        • de Mouzon J
        • Rosenberg L
        • Stolley PD
        • Warshauer ME
        • et al.
        Estrogen replacement therapy and the risk of breast cancer: results from the Case-Control Surveillance Study.
        Am J Epidemiol. 1991; 134: 1375-1385
        • Palmer JR
        • Rosenberg L
        • Clarke EA
        • Miller DR
        • Shapiro S.
        Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study.
        Am J Epidemiol. 1991; 134: 1386-1395
        • Yang CP
        • Daling JR
        • Band PR
        • Gallagher RP
        • White E
        • Weiss NS.
        Noncontraceptive hormone use and risk of breast cancer.
        Cancer Causes Control. 1992; 3: 475-479
        • La Vecchia C
        • Negri E
        • Franceschi S
        • Favero A
        • Nanni O
        • Filiberti R
        • et al.
        Hormone replacement treatment and breast cancer risk: cooperative Italian study.
        Br J Cancer. 1995; 72: 244-248
        • Persson I
        • Weiderpass E
        • Bergkvist L
        • Bergström R
        • Schairer C.
        Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement.
        Cancer Causes Control. 1999; 10: 253-260
        • Stanford JL
        • Weiss NS
        • Voigt LF
        • Daling JR
        • Habel LA
        • Rossing MA.
        Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.
        JAMA. 1995; 274: 137-142
        • Newcomb PA
        • Longnecker MP
        • Storer BE
        • Mittendorf R
        • Baron J
        • Clapp RW
        • et al.
        Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women.
        Am J Epidemiol. 1995; 142: 788-795
        • Moorman PG
        • Kuwabara H
        • Millikan RC
        • Newman B.
        Menopausal hormones and breast cancer in a biracial population.
        Am J Public Health. 2000; 90: 966-971
        • Schuurman AG
        • van den Brandt PA
        • Goldbohm RA.
        Exogenous hormone use and the risk of postmenopausal breast cancer: results from the Netherlands Cohort Study.
        Cancer Causes Control. 1995; 6: 416-424
        • Levi F
        • Lucchini F
        • Pasche C
        • La Vecchia C.
        Oral contraceptives, menopausal hormone replacement therapy and breast cancer risk.
        Eur J Cancer Prev. 1996; 5: 259-266
        • Persson I
        • Thurfjell E
        • Bergstrom R
        • Holmberg L.
        Hormone replacement therapy and the risk of breast cancer: nested case-control study in a cohort of Swedish women attending mammography screening.
        Int J Cancer. 1997; 72: 758-761
        • Sellers TA
        • Mink PJ
        • Cerhan JR
        • Zheng W
        • Anderson K
        • Kushi LH
        • et al.
        The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer.
        Ann Intern Med. 1997; 127: 973-980
        • Brinton LA
        • Brogan DR
        • Coates RJ
        • Swanson CA
        • Potischman N
        • Stanford JL.
        Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy.
        Menopause. 1998; 5: 145-151
        • Henrich JB
        • Kornguth PJ
        • Viscoli CM
        • Horwitz RI.
        Postmenopausal estrogen use and invasive versus in situ breast cancer risk.
        J Clin Epidemiol. 1998; 51: 1277-1283
        • Lando JF
        • Heck KE
        • Brett KM.
        Hormone replacement therapy and breast cancer risk in a nationally representative cohort.
        Am J Prev Med. 1999; 17: 176-180
        • Nachtigall LE
        • Nachtigall RH
        • Nachtigall RD
        • Beckman EM.
        Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems.
        Obstet Gynecol. 1979; 54: 74-79
        • Writing Group for the Women's Health Initiative Investigators
        Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.
        JAMA. 2002; 288: 321-333
        • Dupont WD
        • Page DL
        • Parl FF
        • Plummer Jr, WD
        • Schuyler PA
        • Kasami M
        • et al.
        Estrogen replacement therapy in women with a history of proliferative breast disease.
        Cancer. 1999; 85: 1277-1283
        • Plu-Bureau G
        • Le MG
        • Sitruk-Ware R
        • Thalabard JC
        • Mauvais-Jarvis P.
        Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease.
        Br J Cancer. 1994; 70: 270-277
        • Col NF
        • Hirota LK
        • Orr RK
        • Erban JK
        • Wong JB
        • Lau J.
        Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk.
        J Clin Oncol. 2001; 19: 2357-2363
        • O'Meara ES
        • Rossing MA
        • Daling JR
        • Elmore JG
        • Barlow WE
        • Weiss NS.
        Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality.
        J Natl Cancer Inst. 2001; 93: 754-761
        • Eden JA
        • Bush T
        • Nand S
        • Wren BG.
        A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer.
        Menopause. 1995; 2: 67-72
        • Dew J
        • Eden J
        • Beller E
        • Magarey C
        • Schwartz P
        • Crea P
        • et al.
        A cohort study of hormone replacement therapy given to women previously treated for breast cancer.
        Climacteric. 1998; 1: 137-142
        • Eden JA
        • Durna EM
        • Wren BG
        • Heller G
        • Leader LR.
        ([abstract])HRT after breast cancer: the latest results from the Royal Hospital for Women breast cancer study, Proceedings of the 5th Australasian Menopause Society Congress, Melbourne, Australia 2001 The Society, Melbourne23-27 Oct, 2001
        • Cobleigh MA
        • Berris RF
        • Bush T
        • Davidson NE
        • Robert NJ
        • Sparano JA
        • et al.
        Estrogen replacement therapy in breast cancer survivors.
        JAMA. 1994; 272: 540-545
        • Durna EM
        • Wren BG
        • Heller GZ
        • Leader LR
        • Sjoblom P
        • Eden JA.
        Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality.
        Med J Aust. 2002; 177: 347-351
        • Cuzick J.
        Is hormone replacement therapy safe for breast cancer patients?.
        J Natl Cancer Inst. 2001; 93: 733-734
        • Greendale GA
        • Reboussin BA
        • Sie A
        • Singh HR
        • Olson LK
        • Gatewood O
        • et al.
        Effects of estrogen and estrogen-progestin on mammographic parenchymal density.
        Ann Intern Med. 1999; 4: 262-269
        • Laya MB
        • Gallagher JC
        • Schreiman JS
        • Larson EB
        • Watson P
        • Weinstein L.
        Effect of postmenopausal hormone replacement therapy on mammographic density and parenchymal pattern.
        Radiology. 1995; 196: 433-437
        • McNicholas MM
        • Heneghan JP
        • Milner MH
        • Tunney T
        • Hourihane JB
        • MacErlaine DP.
        Pain and increased mammographic density in women receiving hormone replacement therapy: a prospective study.
        AJR Am J Roentgenol. 1994; 163: 311-315
        • Lundström E
        • Wilczek B
        • von Palffy Z
        • Söderqvist G
        • von Schoultz B.
        Mammographic breast density during hormone replacement therapy: differences according to treatment.
        Am J Obstet Gynecol. 1999; 181: 348-352
        • Persson I
        • Thurfjell E
        • Holmberg L.
        Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density.
        J Clin Oncol. 1997; 15: 3201-3207
        • Sterns EE
        • Zee B.
        Mammographic density changes in perimenopausal and postmenopausal women: is effect of hormone replacement therapy predictable?.
        Breast Cancer Res Treat. 2000; 59: 125-132
        • Erel CT
        • Seyisoglu H
        • Senturk ML
        • Akman C
        • Ersavasti G
        • Benian A
        • et al.
        Mammographic changes in women on hormonal replacement therapy.
        Maturitas. 1996; 25: 51-57
        • Stomper PC
        • Van Voorhis BJ
        • Ravnikar VA
        • Meyer JE.
        Mammographic changes associated with postmenopausal hormone replacement therapy: a longitudinal study.
        Radiology. 1990; 174: 487-490
        • Ozdemir A
        • Konus O
        • Nas T
        • Erba G
        • Cosar S
        • Isik S.
        Mammographic and ultrasonographic study of changes in the breast related to HRT.
        Int J Gynaecol Obstet. 1999; 67: 23-32
        • Colacurci N
        • Fornaro F
        • de Franciscis P
        • Mele D
        • Palermo M
        • del Vecchio W.
        Effects of a short-term suspension of hormone replacement therapy on mammographic density.
        Fertil Steril. 2001; 76: 451-455
        • Sendag F
        • Cosan Terek M
        • Ozsener S
        • Oztekin K
        • Bilgin O
        • Bilgen I
        • et al.
        Mammographic density changes during different postmenopausal hormone replacement therapies.
        Fertil Steril. 2001; 76: 445-450
        • Rutter CM
        • Mandelson MT
        • Laya MB
        • Seger DJ
        • Taplin S.
        Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy.
        JAMA. 2001; 285: 171-176
        • Harvey JA
        • Pinkerton JV
        • Herman CR.
        Short-term cessation of hormone replacement therapy and improvement of mammographic specificity.
        J Natl Cancer Inst. 1997; 89: 1623-1625
        • Boyd NF
        • Byng JW
        • Jong RA
        • Fishell EK
        • Little LE
        • Miller AB
        • et al.
        Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study.
        J Natl Cancer Inst. 1995; 87: 670-675
        • Kato I
        • Beinart C
        • Bleich A
        • Su S
        • Kim M
        • Toniolo PG.
        A nested case-control study of mammographic patterns, breast volume, and breast cancer (New York City).
        Cancer Causes Control. 1995; 6: 431-438
        • Byrne C
        • Schairer C
        • Wolfe J
        • Parekh N
        • Salane M
        • Brinton LA
        • et al.
        Mammographic features and breast cancer risk: effects with time, age, and menopause status.
        J Natl Cancer Inst. 1995; 87: 1622-1629
        • Speroff L.
        Postmenopausal estrogen-progestin therapy and breast cancer: a clinical response to an epidemiologic report.
        Contemp OB/GYN. 2000; : 103-122
        • Stomper PC
        • D’Souza DJ
        • DiNitto PA
        • Arredondo MA.
        Analysis of parenchymal density on mammograms in 1353 women 25-79 years old.
        AJR Am J Roentgenol. 1996; 167: 1261-1265
        • Shoupe D.
        HRT dosing regimens: continuous versus cyclic—pros and cons.
        Int J Fertil. 2001; 45: 7-15
        • Hunt K
        • Vessey M
        • McPherson K.
        Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis.
        Br J Obstet Gynaecol. 1990; 97: 1080-1086
        • Henderson BE
        • Paganini-Hill A
        • Ross RK.
        Decreased mortality in users of estrogen replacement therapy.
        Arch Intern Med. 1991; 151: 75-78
        • Grodstein F
        • Stampfer MJ
        • Colditz GA
        • Willett WC
        • Manson JE
        • Joffe M
        • et al.
        Postmenopausal hormone therapy and mortality.
        N Engl J Med. 1997; 336: 1769-1775
        • Willis DB
        • Calle EE
        • Miracle-McMahill HL
        • Heath Jr., CW
        Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States.
        Cancer Causes Control. 1996; 7: 449-457
        • Bergkvist L
        • Adami H-O
        • Persson I
        • Bergström R
        • Krusemo UB.
        Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy.
        Am J Epidemiol. 1989; 130: 221-228
        • Bonnier P
        • Romain S
        • Giacalone PL
        • Laffargue F
        • Martin PM
        • Piana L.
        Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy.
        Obstet Gynecol. 1995; 85: 11-17
        • Persson I
        • Yuen J
        • Bergkvist L
        • Schairer C.
        Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy—long-term follow-up of a Swedish cohort.
        Int J Cancer. 1996; 67: 327-332
        • Schairer C
        • Gail M
        • Byrne C
        • Rosenberg PS
        • Sturgeon SR
        • Brinton LA
        • et al.
        Estrogen replacement therapy and breast cancer survival in a large screening study.
        J Natl Cancer Inst. 1999; 91: 264-270
        • Fowble B
        • Hanlon A
        • Freedman G
        • Patchefsky A
        • Kessler H
        • Nicolaou N
        • et al.
        Postmenopausal hormone replacement therapy: effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation.
        J Clin Oncol. 1999; 17: 1680-1688
        • Jernstrom H
        • Frenander J
        • Ferno M
        • Olsson H.
        Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients.
        Br J Cancer. 1999; 80: 1453-1458
        • DiSaia PJ
        • Brewster WR
        • Ziogas A
        • Anton-Culver H.
        Breast cancer survival and hormone replacement therapy: a cohort analysis.
        Am J Clin Oncol. 2000; 23: 541-545
        • LaCroix AZ
        • Burke W.
        Breast cancer and hormone replacement therapy.
        Lancet. 1997; 350: 1042-1043
        • Gajdos C
        • Tartter PI
        • Babinszki A.
        Breast cancer diagnosed during hormone replacement therapy.
        Obstet Gynecol. 2000; 95: 513-518
        • Bonnier P
        • Bessenay F
        • Sasco AJ
        • Beedassy B
        • Lejeune C
        • Romain S
        • et al.
        Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer.
        Int J Cancer. 1998; 79: 278-282
        • Salmon RJ
        • Ansquer Y
        • Asselain B
        • Languille O
        • Lesec G
        • Remvikos Y.
        Clinical and biological characteristics of breast cancers in post-menopausal women receiving hormone replacement therapy for menopause.
        Oncol Rep. 1999; 6: 699-703
        • Holli K
        • Isola J
        • Cuzick J.
        Low biologic aggressiveness in breast cancer in women using hormone replacement therapy.
        J Clin Oncol. 1998; 16: 3115-3120
        • O'Connor IF
        • Shembekar MV
        • Shousha S.
        Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study.
        J Clin Pathol. 1998; 51: 935-938
        • Magnusson C
        • Holmberg L
        • Norden T
        • Lindgren A
        • Persson I.
        Prognostic characteristics in breast cancers after hormone replacement therapy.
        Breast Cancer Res Treat. 1996; 38: 325-334
        • Squitieri R
        • Tartter PI
        • Ahmed S
        • Brower ST
        • Theise ND.
        Carcinoma of the breast in postmenopausal hormone user and nonuser control groups.
        J Am Coll Surg. 1994; 178: 167-170
        • Harding C
        • Knox WF
        • Faragher EB
        • Baildam A
        • Bundred NJ.
        Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit.
        BMJ. 1996; 312: 1646-1647
        • Bilimoria MM
        • Winchester DJ
        • Sener SF
        • Motykie G
        • Sehgal UL
        • Winchester DP.
        Estrogen replacement therapy and breast cancer: analysis of age of onset and tumor characteristics.
        Ann Surg Oncol. 1999; 6: 200-207
        • Strickland DM
        • Gambrell Jr, RD
        • Butzin CA
        • Strickland K.
        The relationship between breast cancer survival and prior postmenopausal estrogen use.
        Obstet Gynecol. 1992; 80: 400-404
        • Cobleigh MA
        • Norlock FE
        • Oleske DM
        • Starr A.
        Hormone replacement therapy and high S phase in breast cancer.
        JAMA. 1999; 281: 1528-1530